Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
This is what you will do: Publication Lead collaborates with the Japan Medical Directors across-TAs as well as with the TA -specific Sci comms leads and medical directors. The successful Publication Lead will engage with internal
This is what you will do: Publication Lead collaborates with the Japan Medical Directors across-TAs as well as with the TA -specific Sci comms leads and medical directors. The successful Publication Lead will engage with internal
At Johnson & Johnson,we believe health is everything. Our strength in healthcare innovation empowers us to build aworld where complex diseases are prevented, treated, and cured,where treatments are smarter and less invasive, andsolutions are personal.Through our